FeesSafety
Pluang+

A record 1.28 billion barrels of oil stuck at sea may keep gas prices high despite falling crude prices.

Market News
08 Nov 2026, 18:17 WIB
24/7 Wall Street
View Source
Bearish
A record 1.28 billion barrels of oil stuck at sea may keep gas prices high despite falling crude prices.

A record 1.28 billion barrels of crude oil are currently stuck on tankers at sea, delaying delivery to refineries. This buildup is due to longer shipping routes and slower ship-to-ship transfers following disruptions in Middle Eastern supply routes. Although crude oil prices have fallen, high shipping costs now make up over 30% of the cost per barrel, limiting relief for gas prices. Drivers may continue to face gas prices above $4 per gallon until these logistical issues ease and oil reaches refineries.

The record 1.28 billion barrels of oil stuck at sea provide context for energy market dynamics. For readers following energy stocks, here is Pluang's market snapshot as of Nov 08, 2026 23:31 WIB: Of 79 priced Energy-sector US stocks, 41 rose and 37 fell. Notable moves include CCJ (Cameco) up 4.35% at USD 71.30 with a typical hold time of 18 days, TS (Tenaris S.A.) up 4.10% at USD 58.85 with an 11-day hold, and KOS (Kosmos Energy Ltd.) down 4.09% at USD 2.11 with a 3-day hold.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
1 hour ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
1 hour ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
1 hour ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
1 hour ago
Anthropic's $895B AI contract commitments pose major risks to suppliers and Wall Street debt markets.

Anthropic's $895B AI contract commitments pose major risks to suppliers and Wall Street debt markets.

Anthropic has committed $895.4 billion to future AI infrastructure contracts, heavily impacting suppliers like Broadcom, Alphabet, and Amazon, who are already burning cash to meet these obligations. This massive spending commitment, revealed in Anthr...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App